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Abstract
Background: Canine cutaneous mast cell tumor (MCT) is a common neoplastic disease
associated with a variable biologic behavior. Surgery remains the primary treatment for canine
MCT; however, radiation therapy (RT) and chemotherapy are commonly used to treat aggressive
MCT. The goals of this study were to evaluate the prognostic utility of histologic grade, c-KIT
mutations, KIT staining patterns, and the proliferation markers Ki67 and AgNORs in dogs
postoperatively treated with vinblastine and prednisone +/- RT, and to compare the outcome of
dogs treated with post-operative chemotherapy +/- RT to that of a prognostically matched group
treated with surgery alone. Associations between prognostic markers and survival were evaluated.
Disease-free intervals (DFI) and overall survival times (OS) of dogs with similar pretreatment
prognostic indices postoperatively treated with chemotherapy were compared to dogs treated
with surgery alone.
Results: Histologic grade 3 MCTs, MCTs with c-KIT mutations, MCTs with increased cytoplasmic
KIT, and MCTs with increased Ki67 and AgNOR values were associated with decreased DFI and
OS. Dogs with histologic grade 3 MCT had significantly increased DFI and OS when treated with
chemotherapy vs. surgery alone. Although not statistically significant due to small sample sizes,
MCTs with c-KIT mutations had increased DFI and OS when treated with chemotherapy vs. surgery
alone.
Conclusion and clinical importance: This study confirms the prognostic value of histologic
grade, c-KIT mutations, KIT staining patterns, and proliferation analyses for canine MCT.
Additionally, the results of this study further define the benefit of postoperative vinblastine and
prednisone for histologic grade 3 MCTs.
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Canine cutaneous mast cell tumor (MCT) is a common
neoplastic disease in dogs, accounting for 7–21% of all
cutaneous neoplasms [1-4]. Canine MCTs have variable
biologic behaviors, ranging from solitary benign masses
that can be cured with surgery alone to systemic and
potentially fatal metastatic disease [5-9]. Currently, surgi-
cal excision is the primary treatment modality for canine
MCT. In the event of incomplete surgical excision or a
non-resectable tumor, radiation therapy (RT) may be used
as an adjunct local therapy, and in the face of multicentric,
metastatic, or aggressive MCT, postoperative chemother-
apy is commonly employed. Canine mast cell tumors
have variable response rates to different chemotherapy
protocols, and, as with any drug, there is potential for the
development of serious adverse events as a result of chem-
otherapy administration[6,8]. Therefore, it is critical to
identify patients that will benefit most from such treat-
ments and to identify prognostic markers that are associ-
ated with specific treatment outcomes.
Previously, our laboratory has evaluated the prognostic
significance of several markers for canine MCT patients
treated with surgery alone. In these studies we found that
KIT staining patterns[10], c-KIT internal tandem duplica-
tion (ITD) mutations[11], and cellular proliferation as
measured by Ki67 immuno-staining and AgNOR histo-
chemical staining[12] are significantly associated with the
progression of canine MCT when treated with surgery
alone. Although the results of these studies demonstrate
the utility of these markers as diagnostic and prognostic
tools for MCT treated with surgery alone, they do not pro-
vide information regarding their association with the out-
come of patients treated with postoperative RT or
chemotherapy.
Combination chemotherapy with vinblastine and pred-
nisone has been previously suggested to be an efficacious
postoperative therapy for a subset of MCT patients[13];
however, no clear determinants have been identified to
discriminate between MCTs that are likely to benefit from
vinblastine and prednisone and those that are not. There-
fore, the primary goal of this study was to evaluate the
prognostic significance of histologic grade; c-KIT ITD
mutation; KIT staining patterns; and the proliferation
markers Ki67 and AgNORs for dogs treated with vinblast-
ine and prednisone following surgery +/- RT. Addition-
ally, in order to better determine the efficacy of
postoperative vinblastine and prednisone, an additional
goal of this study was to compare the outcomes of dogs
postoperatively treated with vinblastine and prednisone
+/- RT to those treated with surgery alone, when stratified
based on identified prognostic markers. The results of this
paper show that histologic grade; c-KIT ITD mutation; KIT
staining patterns; and the proliferation markers Ki67 and
AgNORs are prognostically significant for dogs with MCTs
treated with vinblastine and prednisone following surgery
+/- RT. Additionally, this study strongly suggests that dogs
with grade 3 MCTs benefit from post-operative chemo-
therapy treatment when compared to treatment with sur-
gery alone.
Results
Twenty-eight MCTs dogs postoperatively treated with vin-
blastine and prednisone +/- RT were included in this
study. Fourteen dogs were female and 14 were male. Dogs
ranged from 2 to 14 years of age (mean = 9.29 years) and
represented 16 breeds including mixed breed dogs (9),
Labrador retrievers (4), Gordon setters (2), and 13 other
breeds which were represented by single animals. Ten
tumors were histologic grade 3 MCT and 18 were grade 2.
Four MCTs, all of which were histologic grade 3 tumors,
had ITD c-KIT mutations. Two MCTs had pattern 1 KIT
protein expression, 6 MCTs had KIT pattern 3, and 20
MCTs had KIT pattern 2.
Results of multivariable analyses are presented in Table 1.
According to multivariable analyses, dogs with histologic
Table 1: Multivariate analyses of associations between prognostic factors and patient outcome.
Variable N Median DFI* DFI p-value Median OS time# OS time p-value
(months) (months)
Histologic grade
Grade 2 18 14.1 0.022 21.5 0.01
Grade 3 10 7 9.2
KIT staining pattern+
Pattern 2 20 12.7 0.0022 19 0.0049
Pattern 3 6 6.7 10.8
c-KIT mutation
No 24 11 0.0413 17.4 0.0112
Yes 4 6.5 8.9
*DFI: disease-free interval.
#OS: overall survival.
+Two KIT pattern 1 MCTs were excluded from statistical analyses.Page 2 of 8
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nificantly shorter disease-free intervals (DFI) (p = 0.0220
and p = 0.0413, respectively) and overall survival times
(OS) (p = 0.010 and p = 0.0112, respectively) compared
to dogs with grade 2 MCT and dogs lacking c-KIT muta-
tions, respectively (Figures 1 and 2). Tumors with KIT
staining pattern 3 were significantly associated with
decreased DFI and OS compared to tumors with KIT pat-
tern 2 (p = 0.0022 and p = 0.0049, respectively; Figure 3).
Increased Ki67 expression and AgNOR values were associ-
ated with decreased DFI (p = 0.0386 and p = 0.0168,
respectively) and decreased OS (p = 0.0097 and p =
0.0066, respectively) [12].
Although previous studies have described patient survival
following postoperative treatment with vinblastine and
prednisone[13], no studies have compared the outcome
of treatment with vinblastine and prednisone to that of
surgery alone in a similar group of dogs. In order to retro-
spectively evaluate the efficacy of postoperative vinblast-
ine and prednisone, survival curves representing DFI and
OS times were compared between dogs treated in this
study and dogs treated with surgery alone that were eval-
uated as part of previous studies[10-12,14]. As a means of
ensuring that similar populations of animals were com-
pared, comparisons were made between groups of ani-
mals that had similar pre-treatment prognoses based on
histologic grade, KIT staining pattern, and the presence of
ITD c-KIT mutations.
According to multivariable analyses, dogs with histologic
grade III MCT treated with surgery alone had significantly
shorter DFI (1 month vs. 7 months, p = 0.0082) and OS
times (1 month vs. 9.2 months, p = 0.0427) compared to
dogs treated with vinblastine and prednisone (Figure 4).
Dogs with KIT pattern 2 MCT treated with surgery alone
had significantly shorter OS times compared to those
treated with vinblastine and prednisone (16.6 months vs.
19 months, p = 0.0362). Mast cell tumors with c-KIT
mutations treated with vinblastine and prednisone
tended to have increased DFI (1 month vs. 6.5 months)
and OS times (1 month vs. 8.9 months); however, these
associations were not statistically significant (Figure 5).
Discussion
In this study, treatment with vinblastine and prednisone
following surgery +/- RT benefited dogs with grade III
MCT over treatment with surgery alone. The results of this
study further validate the use of postoperative vinblastine
and prednisone for histologic grade III MCT. Additionally,
dogs with c-KIT mutations that were treated with vinblas-
tine and prednisone tended to have longer DFI and OS
times as compared to those treated with surgery alone,
although this association was not statistically significant.
This lack of statistical significance might be due to the rel-
atively low number of cases with c-KIT mutations evalu-
ated or the similar relative frequency of DFI and OS after
5 and 10 months, respectively. Additionally, 2/9 dogs
with c-KIT mutations treated with surgery alone survived
greater than 20 months. However, one mutation was con-
fined to intron 11; therefore the biologic significance of
this mutation is unknown[11]. The difference in median
OS times between MCTs with c-KIT mutations treated
with local therapy alone and those treated with vinblast-
ine and prednisone suggests that MCTs with c-KIT muta-
Survival curves of dogs with histologic grade 2 and 3 MCTsFigure 1
Survival curves of dogs with histologic grade 2 and 3 MCTs. Kaplan-Meier survival curves comparing disease-free inter-
val (A) and overall survival times (B) of dogs with histologic grade 2 and 3 MCTs.Page 3 of 8
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chemotherapy with vinblastine and prednisone.
In a previous study, we showed MCTs treated with surgery
alone with more than 23 Ki67-positive cells per grid area
or a Ki67 × AgNOR (Ag67) value of more than 53 per grid
area were associated with decreased patient survival[12];
however, in this study, these cut-off values did not dis-
criminate patient survival. Interestingly, in this study only
2/14 dogs with Ki67 indices < 23 died by the end of this
study, while 8/14 dogs with Ki67 indices > 23 died. Simi-
larly only 1/14 dogs with Ag67 indices < 53 died, while 9/
14 dogs with Ag67 indices > 53 died by the end of this
study. The lack of statistical significance in this study is
likely due to variations in the patient populations of these
studies and the small population size in this study. Our
previous study included 8 dogs with histologic grade 1
MCT, while this study only included grade 2 and grade 3
MCTs. Additionally, all cases included in this study
received chemotherapy, suggesting that as a whole, this
study was biased towards more aggressive MCT.
Survival curves of dogs with and without c-KIT mutationsFigure 2
Survival curves of dogs with and without c-KIT mutations. Kaplan-Meier survival curves comparing disease-free interval 
(A) and overall survival times (B) of dogs with and without c-KIT mutations.
Survival curves of dogs with different KIT staining patternsFigure 3
Survival curves of dogs with different KIT staining patterns. Kaplan-Meier survival curves comparing disease-free inter-
val (A) and overall survival times (B) of dogs with MCTs with different KIT staining patterns.Page 4 of 8
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tions, KIT staining patterns, and proliferation markers,
Ki67 and AgNORs, were associated with the prognosis of
MCT postoperatively treated with vinblastine and pred-
nisone. Compared with grade 2 MCTs, histologic grade 3
MCTs were significantly associated with decreased DFI
and OS times. Additionally, dogs with grade 3 MCT signif-
icantly benefited from treatment with vinblastine and
prednisone. These results support the use of histologic
grading for the prognostication of canine MCT; however,
interobserver variations and the unpredictable behavior
of grade 2 MCT continue to limit the utility of histologic
Survival curves of dogs with grade 3 MCTs treated with surgery alone or with post-operative chemotherapyFigure 4
Survival curves of dogs with grade 3 MCTs treated with surgery alone or with post-operative chemotherapy. 
Kaplan-Meier survival curves comparing disease-free interval (A) and overall survival times (B) of dogs with histologic grade 3 
MCT treated with surgery alone or with vinblastine and prednisone in addition to surgery.
Survival curves of dogs with c-KIT mutations treated with surgery alone or with post-operative chemotherapyFigure 5
Survival curves of dogs with c-KIT mutations treated with surgery alone or with post-operative chemotherapy. 
Kaplan-Meier survival curves comparing disease-free intervals (A) and overall survival times (B) of dogs with c-KIT mutations 
treated with surgery alone or with vinblastine and prednisone in addition to surgery.Page 5 of 8
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Therefore, in the face of intermediate grade MCTs, histo-
logic grade should be complemented with additional
prognostic markers, such as KIT immunohistochemistry,
c-KIT mutation evaluation, and proliferation markers
using Ki67 and Ag67 cut-off values of 23 and 53, respec-
tively. No single marker can successfully identify all MCTs
that will result in death; therefore, a panel of markers
should be used in order to evaluate the entire spectrum of
the disease.
Major limitations of this study include the levels of histor-
ical inaccuracy associated with any retrospective study,
small samples sizes in some subgroups, and variations in
treatment and staging; most notably the fact that 50% of
the chemotherapy treated patients received RT. However,
dogs treated with chemotherapy and radiation therapy
did not have significantly different times to treatment fail-
ure or overall survival times as compared to those treated
without radiation therapy (log rank p-value = 0.223 and p
= 0.314, respectively). An additional limitation of this
study was that many of the control treated animals were
treated in primary care private practices, while those
treated with chemotherapy were treated at a single referral
practice. Differences in care between clinicians and hospi-
tals might further affect treatment outcomes; however,
data available from for this study do not allow us to eval-
uate this effect.
Conclusion
The results of this study add further credence supporting
the use of histologic grade, c-KIT mutations, and KIT pro-
tein localization for the prognostication of canine MCTs.
Additionally, these results further support that hypothesis
that c-KIT mutations and intracellular localization of the
KIT protein both contribute to the progression of canine
MCT. Finally, although previous studies have evaluated
the use of vinblastine and prednisone for the treatment of
high-risk MCTs, this is the first study to compare the out-
come of animals treated with adjuvant vinblastine and
prednisone +/- RT to a prognostically matched group of
animals treated with surgery alone. Although retrospec-
tive studies provide critical, relevant information regard-
ing the utility of treatments and prognostic markers,
controlled, blinded prospective studies remain the gold
standard for evaluating therapeutics and prognostic mark-
ers and the data presented here need to be corroborated in
a controlled, prospective study in order to truly define
their prognostic significance. In the future, prospective
evaluations of new therapeutics should not only be
focused on the safety and efficacy of the therapy, but also
on identifying biomarkers including histopathology, clin-
ical pathology, and molecular biology-based markers
associated with outcome.
Methods
Twenty-eight canine cutaneous MCTs from 28 dogs
included in this study were identified as part of a larger
retrospective study[13] with the goals of: 1. evaluating the
combination of vinblastine and prednisone as postopera-
tive chemotherapy for canine MCT following surgical exci-
sion +/- RT; and 2. identifying clinical prognostic factors
associated with this treatment. All cases were treated at the
University of Wisconsin – Madison Veterinary Medical
Teaching Hospital and were included in this study based
on the following inclusion criteria: 1. absence of severe
concurrent disease; 2. complete staging; 3. no concurrent
systemic antineoplastic therapy other then prednisone
and vinblastine; 4. absence of measurable disease follow-
ing surgery; 5. confirmed histologic diagnosis of canine
cutaneous MCT; 6. adequate tissues available for c-KIT
polymerase chain reaction and immunohistochemistry.
Prednisone was administered at an initial dose of 2 mg/kg
PO daily, and tapered over 12–26 weeks. Vinblastine was
administered at 2 mg/m2 as a rapid intravenous bolus
weekly for 4 weeks, followed by 4 biweekly treatments.
One dog was given a total of 16 vinblastine treatments, as
treatment was re-initiated at the time of disease recur-
rence. Tumors were considered to have been treated with
"adequate local therapy" when tumors were completely
excised with no evidence of neoplastic mast cells at the
surgical margins or when surgical excision was performed
with subsequent local RT. According to these standards,
adequate local therapy was obtained in 24 of 28 dogs.
Four dogs had histologic evidence of microscopic disease
at the surgical site at the time that chemotherapy was ini-
tiated. Three of these dogs had histologic grade 2 MCT and
one dog had grade 3 MCT. Postoperative RT was per-
formed in 14 patients, and regional lymph nodes were
irradiated in 10 of these patients. Eleven dogs received 4
once-weekly, 8 Gray radiation treatments; one dog
received 4 once weekly, 6.5 Gray treatments; and 2 dogs
received 15 daily (M-F) treatments of 3.2 Gray each. His-
tologic grade of each tumor was confirmed according to
the Patnaik histologic grading system for canine cutane-
ous MCT by a single pathologist[7]. Complete clinical
staging was performed in all patients, and included phys-
ical examination, complete blood count, serum biochem-
istry profile, abdominal ultrasound, and regional lymph
node palpation with or without fine needle aspiration
cytology. Lymph nodes were only considered positive for
lymph node metastasis if they contained clusters or sheets
of mast cells; scattered individual mast cells were not suf-
ficient to diagnose lymph node metastasis. A control pop-
ulation of 56 dogs with canine MCT treated with surgery
alone, which were evaluated as part of a previous
study[12], were used to compare outcomes between dogs
treated with surgery alone and those treated with surgery
and postoperative chemotherapy. These cases were sub-
mitted as routine biopsies to the Diagnostic Center forPage 6 of 8
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veterinarians; therefore, clinical staging was not standard-
ized among these cases. Of these 56 dogs, 8 dogs had his-
tologic grade 1 MCT, 41 dogs had grade 2 MCT, and 7
dogs had grade 3 MCT. Nine of these dogs had internal
tandem duplication c-KIT mutations.
Immunohistochemical staining, AgNOR staining; evalua-
tion of KIT staining patterns, evaluation of proliferation
indices as measured by Ki67 labeling and AgNOR stain-
ing, and analysis of c-KIT mutations were performed as
previously described[12] In brief, 3 patterns of KIT protein
localization were identified: 1. KIT pattern I, which con-
sisted of a predominately peri-membrane pattern of KIT
protein localization with minimal cytoplasmic KIT pro-
tein localization; 2. KIT pattern II, which consisted of focal
to stippled cytoplasmic KIT protein localization; and 3.
KIT pattern III, which consisted of diffuse KIT cytoplasmic
KIT protein localization. Each MCT was classified based
on the highest staining pattern present in at least 10%
(estimated based on 100 neoplastic cells in a high power
field) of the neoplastic cell population or being present in
large clusters. For Ki67 immunohistochemical staining
evaluations, areas with the highest proportion of
immuno-positive neoplastic mast cells were identified at
100× magnification using an American Optical light
microscope. The number of immuno-positive cells
present in a 10 mm × 10 mm grid area was counted using
a 1 cm2 10 × 10 grid reticle at 400× magnification. The
number of immuno-positive cells per grid area was evalu-
ated in 5 high powered fields and subsequently averaged
in order to obtain the growth fraction. In order to deter-
mine the average AgNOR count/cell in each tumor,
AgNORs were counted in 100 randomly selected neoplas-
tic mast cells throughout the tumor at 1000× magnifica-
tion. Individual AgNORs were resolved by focusing up
and down while counting within individual nuclei. Aver-
age AgNOR counts/cell was determined based on averag-
ing these counts.
Statistical Analysis
This study used two different approaches to analysis: log-
rank models(SAS PROC LIFETEST) to describe associa-
tions between risk factors and the occurrence (yes/no) of
MCT outcomes, and the Cox proportional hazards models
(SAS PROC PHREG)b for survival analysis to describe the
relationships between risk factors and the time to the
occurrence of different MCT outcomes (time-to-event).
Survival analysis produces point estimates of the hazard
ratio (risk ratio) for risk factors in the model. The MCT
outcomes used in this study included disease-free interval
and overall survival time. Median times for disease-free
interval (DFI) and overall survival (OS) times were
reported as the time from treatment initiation to event or
last follow-up. Disease-free interval was defined as the
time until local recurrence, development of metastatic dis-
ease, or development of a new mast cell tumor.
Univariable Analyses
Before developing multivariable models, each risk factor
was evaluated for its association with MCT outcomes.
Both univariable log-rank (for occurrence) and propor-
tional hazards (for time to event) models were developed
for each risk factor for each outcome, and the level of asso-
ciation was assessed through the risk factor's p-value in
the model. Risk factors with p less than or equal to 0.20
were considered for inclusion in the multivariable mod-
els.
Multivariable Survival Analysis Models
Multivariable proportional hazards regression models
were developed for survival analysis of different outcomes
associated with MCT, DFI and OS. As for the multivariable
log-rank models, animal signalment (age, sex, weight)
was included in the multivariable models to account for
their effects on model outcomes. The effects of risk factors
on days to events were reported as p-values. The cut off for
significance of the multivariate analysis was set a p < 0.05.
Abbreviations
Disease-free intervals: DFI; mast cell tumor: MCT; overall
survival times: OS; radiation therapy: RT.
Authors' contributions
JDW coordinated the study, performed histologic and
immunohistologic evaluations, performed polymerase
chain reactions, and drafted the manuscript. VY–G and
MK designed the study and oversaw all post-clinical
aspects of the study. EH performed all statistical analyses.
DHT collected all clinical data. All authors helped inter-
pret results and have read and approved the final manu-
script.
Acknowledgements
This work was partially funded by a Companion Animal Fund Grant from 
Michigan State University College of Veterinary Medicine. Joshua Webster 
was supported by NIH T-32 post-doctoral training grant RR17189. An 
abstract of this work has been submitted for the 58th American College of 
Veterinary Pathologists Annual Meeting in November 2007.
References
1. Brodey RS: Canine and feline neoplasia.  Adv Vet Sci Comp Med
1970, 14:309-354.
2. Finnie JW, Bostock DE: Skin neoplasia in dogs.  Aust Vet J 1979,
55(12):602-604.
3. Priester WA: Skin tumors in domestic animals. Data from 12
United States and Canadian colleges of veterinary medicine.
J Natl Cancer Inst 1973, 50(2):457-466.
4. Rothwell TL, Howlett CR, Middleton DJ, Griffiths DA, Duff BC: Skin
neoplasms of dogs in Sydney.  Aust Vet J 1987, 64(6):161-164.
5. Bostock DE: The prognosis following surgical removal of mas-
tocytomas in dogs.  J Small Anim Pract 1973, 14(1):27-41.
6. Misdorp W: Mast cells and canine mast cell tumours. A
review.  Vet Q 2004, 26(4):156-169.Page 7 of 8
(page number not for citation purposes)
BMC Veterinary Research 2008, 4:32 http://www.biomedcentral.com/1746-6148/4/32Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
7. Patnaik AK, Ehler WJ, MacEwen EG: Canine cutaneous mast cell
tumor: morphologic grading and survival time in 83 dogs.  Vet
Pathol 1984, 21(5):469-474.
8. Thamm DH, Vail DM: Mast cell tumors.  In Small Animal Clinical
Oncology 3rd edition. Edited by: Withrow SJ, MacEwen EG. Philadel-
phia, PA , W.B. Saunders; 2001:261-282. 
9. Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the jux-
tamembrane domain of c-KIT are associated with higher
grade mast cell tumors in dogs.  Vet Pathol 2002, 39(5):529-535.
10. Webster JD, Kiupel M, Kaneene JB, Miller R, Yuzbasiyan-Gurkan V:
The use of KIT and tryptase expression patterns as prognos-
tic tools for canine cutaneous mast cell tumors.  Vet Pathol
2004, 41(4):371-377.
11. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JA,
Kiupel M: The role of c-KIT in tumorigenesis: evaluation in
canine cutaneous mast cell tumors.  Neoplasia 2006,
8(4):104-111.
12. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M:
Cellular Proliferation in Canine Cutaneous Mast Cell
Tumors: Associations with c-KIT and Its Role in Prognostica-
tion.  Vet Pathol 2007, 44(3):298-308.
13. Thamm DH, Mauldin EA, Vail DM: Prednisone and vinblastine
chemotherapy for canine mast cell tumor--41 cases (1992-
1997).  J Vet Intern Med 1999, 13(5):491-497.
14. Kiupel M, Webster JD, Miller RA, Kaneene JB: Impact of tumour
depth, tumour location and multiple synchronous masses on
the prognosis of canine cutaneous mast cell tumours.  J Vet
Med A Physiol Pathol Clin Med 2005, 52(6):280-286.
15. Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, Gamble
D, Ginn PE, Goldschmidt MH, Hendrick MJ, Howerth EW, Janovitz
EB, Lenz SD, Lipscomb T, Miller E, Misdorp W, Moroff S, Neyens I,
O'Toole D, Ramos-Vara J, Scase TJ, Schulman Y, Smith K, Snyder P,
Southorn E, Stedman NL, Steficek BA, Stromberg PC, Valli VE, Weis-
brode SE, Yager J, Kaneene JB: Microscopic grading of canine
cutaneous mast cell tumors: a multi-institutional review.  Vet
Pathol 2004, 41:576.
16. Northrup NC, Harmon BG, Gieger TL, Brown CA, Carmichael KP,
Garcia A, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL,
Cheng AL, Howerth EW: Variation among pathologists in histo-
logic grading of canine cutaneous mast cell tumors.  J Vet
Diagn Invest 2005, 17(3):245-248.
17. Northrup NC, Howerth EW, Harmon BG, Brown CA, Carmicheal
KP, Garcia AP, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman
NL, Gieger TL: Variation among pathologists in the histologic
grading of canine cutaneous mast cell tumors with uniform
use of a single grading reference.  J Vet Diagn Invest 2005,
17(6):561-564.
18. Seguin B, Leibman NF, Bregazzi VS, Ogilvie GK, Powers BE, Dernell
WS, Fettman MJ, Withrow SJ: Clinical outcome of dogs with
grade-II mast cell tumors treated with surgery alone: 55
cases (1996-1999).  J Am Vet Med Assoc 2001, 218(7):1120-1123.
19. Weisse C, Shofer FS, Sorenmo K: Recurrence rates and sites for
grade II canine cutaneous mast cell tumors following com-
plete surgical excision.  J Am Anim Hosp Assoc 2002, 38(1):71-73.Page 8 of 8
(page number not for citation purposes)
